Geneva, Switzerland – February 21, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins announced new MARtech™ data from FISH analysis of CHO cell lines expressing recombinant proteins was presented today. The data which was presented during the “BioProcess International, European Conference and Exhibition” in Prague, demonstrated that, with MARtech™, transgenes are integrated in a single site on the chromosome within regions of the chromatin that have been shown to be very stable.

The data are results from an ongoing collaboration between Selexis and Dr. Danielle Martinet from the University Hospital in Lausanne under the supervision of Prof. Nicolas Mermod from the University of Lausanne, Switzerland.

“Contrary to traditional approaches for developing mammalian cell lines, we now know that, in contrast to DHFR, MARtech™ is not associated with chromosomal rearrangements nor chromosomal breaks,” said Igor Fisch, Ph.D., President and Chief Executive Officer of Selexis. “This is a significant step forward in the development of stable, high producing mammalian cell lines. The Selexis’ approach to the development of cell lines has shown that the transgene integrates into a single site within the host cell chromosome. MARtech™ routinely results in cell clones expressing over 50 pcd of recombinant monoclonal antibodies within 8 weeks after transfection.”

“The results are an important validation of the mechanism by which Selexis’ MARtech™ functions. The chromosomal characterization of our cell lines by FISH shows a very simple pattern of integration which allows MARtech™ production cell lines to be easily analyzed for regulatory approval,” adds Cori Gorman, Ph.D., M.B.A., Head of Business Development. “The data further demonstrates our commitment to the biopharmaceutical industry for the development of high-quality cell lines for manufacturing.”

Dr. Gorman, presented these FISH data today as part of the Cell Culture and Upstream Processing track.

More About MARtech™

Selexis' patented technology, MARtech™, improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. MARtech™ allows fast cell population generation in 3 weeks (after transfection) and stable cell line development in 8 weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 10 fold.

About Selexis

Selexis is a privately held biotechnology company dedicated to the development of expert services and technologies for comprehensive and rapid solutions for stable, high yield cell line Selexis SA to Present New Data on MARtech™ development and protein manufacturing for therapeutic drugs. The Company’s unique seven step, high through put process, which includes the forth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit http://www.selexis.com

About BioProcess International, European Conference and Exhibition

BioProcess International Conference and Exhibition is a collaboration between IBC’s four successful biopharmaceutical development conferences and BioProcess International, the first and only international publication devoted to the development, scale-up, and manufacture of biotherapeutics and biodiagnostics. The conference is the premier event for a comprehensive update on operational strategies, technologies, regulatory changes, manufacturing production, and process development. The conference consists of four in-depth tracks: 1 - Scaling-up, Economics and Manufacturing Strategies; 2 - Formulation & Drug Delivery; 3 - Cell Culture & Upstream Processing; and 4 - Recovery & Purification. For more information, please visit http://www.ibc-lifesci.com/bpi/2006

This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.

MARtech™ is a trademark of Selexis, SA.